Technical Analysis for AGRX - Agile Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 3.68% | |
| Gapped Down | Weakness | 3.68% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.60% | |
| 20 DMA Support | Bullish | 3.60% | |
| Outside Day | Range Expansion | 3.60% | |
| Wide Bands | Range Expansion | 3.60% | |
| 180 Bearish Setup | Bearish Swing Setup | 12.08% | |
| Narrow Range Bar | Range Contraction | 12.08% | |
| Outside Day | Range Expansion | 12.08% | |
| Wide Bands | Range Expansion | 12.08% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | about 18 hours ago |
| Possible Inside Day | about 19 hours ago |
| 10 DMA Resistance | about 19 hours ago |
| Up 3% | about 19 hours ago |
| Up 2% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Clinical Development Alcohol Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Clinical Development Alcohol Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.8 |
| 52 Week Low | 0.2 |
| Average Volume | 902,765 |
| 200-Day Moving Average | 1.70 |
| 50-Day Moving Average | 0.60 |
| 20-Day Moving Average | 0.37 |
| 10-Day Moving Average | 0.40 |
| Average True Range | 0.08 |
| RSI (14) | 45.05 |
| ADX | 23.02 |
| +DI | 24.66 |
| -DI | 15.56 |
| Chandelier Exit (Long, 3 ATRs) | 0.37 |
| Chandelier Exit (Short, 3 ATRs) | 0.44 |
| Upper Bollinger Bands | 0.51 |
| Lower Bollinger Band | 0.22 |
| Percent B (%b) | 0.62 |
| BandWidth | 77.90 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0235 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.47 | ||||
| Resistance 3 (R3) | 0.47 | 0.44 | 0.46 | ||
| Resistance 2 (R2) | 0.44 | 0.43 | 0.45 | 0.45 | |
| Resistance 1 (R1) | 0.42 | 0.42 | 0.43 | 0.42 | 0.45 |
| Pivot Point | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
| Support 1 (S1) | 0.38 | 0.38 | 0.39 | 0.38 | 0.35 |
| Support 2 (S2) | 0.35 | 0.37 | 0.35 | 0.35 | |
| Support 3 (S3) | 0.33 | 0.35 | 0.34 | ||
| Support 4 (S4) | 0.33 |
